"Cyclohexanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-carbon alicyclic hydrocarbons.
| Descriptor ID |
D003510
|
| MeSH Number(s) |
D02.455.426.392.368.367
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclohexanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclohexanes".
This graph shows the total number of publications written about "Cyclohexanes" by people in this website by year, and whether "Cyclohexanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 8 | 2 | 10 |
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclohexanes" by people in Profiles.
-
Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease. J Med Chem. 2021 07 22; 64(14):10047-10058.
-
Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol. 2018 02 01; 92(3).
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
-
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. J Antimicrob Chemother. 2017 Nov 01; 72(11):3167-3171.
-
HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites. Virology. 2017 12; 512:222-233.
-
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):384-393.
-
Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy? J Neurol Sci. 2017 Jul 15; 378:233-237.
-
Repurposing a Bacterial Immune System to Discover Antiviral Targets. N Engl J Med. 2017 03 30; 376(13):1290-1291.
-
Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study. Medicine (Baltimore). 2017 Feb; 96(7):e5728.
-
Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. Int J STD AIDS. 2017 10; 28(11):1067-1073.